Products specific to pathogenic strains and their use as vaccines and in immunotherapy
OwnerSonia Escaichinventor
Life of this patent
Estimating the term…
Abstract
The invention relates to isolated antigenic polypeptides obtainable by a process comprising the steps of: 1—selecting on the basis of sequence analysis those of the polypeptides which are either located in the outermembrane or secreted by the bacteria, 2—identifying the genes coding for said polypeptides which are conserved in B2/D clinical isolates, 3—purifying the polypeptides identified in step 1, which are found in step 2 to be conserved in B2/D isolates, 4—testing the polypeptides for immunogenicity using animals models. Application for making vaccines compositions and immunotherapies.
Claims16
The isolated polypeptides having SEQ ID NO0;
- 14, 15, 17, 21, 22, 23, 28, 29, 30, 32, 36, 38, 39, 41-44, 46, 49, 50, 52 to 55, 58, 60, 63, 133-138.
A process for isolating and identifying antigenic polypeptides, useful as vaccines comprising the steps of:
- a—selecting on the basis of sequence analysis those of the polypeptides which are either located in the outermembrane or secreted by the bacteria,
- b—identifying the genes coding for said polypeptides which are conserved in B2/D clinical isolates,
- c—purifying the polypeptides identified in step a, which are found in step b to be conserved in B2/D isolates, d—testing the polypeptides for immunogenicity using animals models.
The use of at least one polypeptide or fragment of these polypeptides selected in the group comprising SEQ ID NO1 to SEQ ID NO66 (except SEQ ID NO8), or 133-145 as antigens and the homologous sequences.
Monoclonal antibodies against epitopes of polypeptide and there use as pharmaceutical compound for treatment or prevention of severe infection due to Expec in neonates and patients at risk for such infections.
Dependencies are inferred from the claim text.